The most clinically relevant risk factor for Clostridioides difficile-associated disease (CDAD) is 13 recent antibiotic treatment. Though most broad-spectrum antibiotics significantly disrupt the 14 structure of the gut microbiota, only particular ones increase CDAD risk, suggesting additional 15 factors might increase the risk from certain antibiotics. Here we show that commensal-independent 16 effects of antibiotics collectively prime an in vitro germ-free human gut for CDAD. We found a 17 marked loss of mucosal barrier and immune function with CDAD-associated antibiotic 18 pretreatment distinct from pretreatment with an antibiotic unassociated with CDAD, which did not 19 reduce innate immune or mucosal barrier functions. Importantly, pretreatment with CDAD-20 associated antibiotics sensitized mucosal barriers to C. difficile toxin activity in primary cell-21 derived enteroid monolayers. These data implicate commensal-independent host changes in the 22 increased risk of CDAD with specific antibiotics. Our findings are contrary to the previously held 23 belief that antibiotics allow for CDAD solely through disruption of the microbiome. We anticipate 24 this work to suggest potential avenues of research for host-directed treatment and preventive 25 therapies for CDAD, and to impact human tissue culturing protocols. 26 27
Introduction 28
Clostridioides difficile-associated disease (CDAD) is a CDC urgent public health threat 1 , with 29 453,000 incident cases in the U.S. in 2011 2 . CDAD is estimated to account for more than 44,500 30 deaths and over $5 billion in related healthcare costs in the United States each year 3 . CDAD 31 treatment failure is increasing due to rising levels of antibiotic resistant and hypervirulent strains 32 of C. difficile (reviewed in 4 ) and high rates of persistent and recurrent infections (reviewed in 5 ). 33
New treatment and prevention strategies are needed. A promising strategy is host directed therapy 6 ; 34 yet, this requires a better understanding of how a person becomes susceptible to CDAD. 35 CDAD pathogenesis requires the outgrowth of the etiologic agent, Clostridioides difficile (C. 36 difficile), in the gastrointestinal tract. While a functional gut microbiome is able to prevent the 37 outgrowth of C. difficile 7 , in large part due to bacterial-dependent production of secondary bile 38 acids 8,9 , loss of a functional gut microbiome allows for outgrowth of the colony. Once quorum is 39 reached, the bacteria begin secreting toxins 8 , specifically TcdB, which is primarily responsible for 40 the disease's symptoms and pathogenesis 9 . 41
The most clinically relevant risk factor for CDAD is recent antibiotic treatment 10 . While there 42 is substantial evidence supporting a causal link between microbiome disruption by antibiotics and 43 CDAD (reviewed in 11 ), the hypothesis that recent antibiotic treatment is the sole causal mechanism 44 for CDAD explains neither the rising rates of CDAD-independent of recent antibiotic 45 treatment 12 -nor the observation that nearly half of all community acquired cases present without 46 prior antibiotic exposure 13 . Furthermore, antibiotic treatment alone produces fewer and less 47 consistent differences in microbial community structure than are observed clinically between 48 patients with and without CDAD 14 . Notwithstanding the frequency of proteobacteria blooms 49 following antibiotic exposure 15 , no shared taxonomic change has been identified in successful fecal 50 microbial transplant donors 16 or recipients 17 , and alterations to bacterial load do not correlate with 51 risk of CDAD 18 . Taken together, these data suggest a previously overlooked commensal-52 independent host contribution to antibiotic-associated risk of CDAD. 53
Recent work has shown that host-acting drugs have a significant effect on bacteria 19 . The 54 inverse has also been shown: a commonly prescribed antibiotic cocktail alters the mitochondrial 55 function of enterocytes in germ-free mice 20 , demonstrating the commensal-independent effect of 56 anti-bacterials on the host in this rodent model. Yet, the effects of CDAD-associated antibiotics on 57 the host-especially the human host-and how these effects might contribute to CDAD is not 58 known. Though previous studies have explored the effects of antibiotics in general on the host in 59 a variety of animal models, isolating the effects of particular antibiotics on host-dependent 60 mechanisms of antibiotic-associated CDAD requires a controlled study assessing these 61 mechanisms for multiple antibiotics with varying degrees of CDAD-associated risk in the same 62 experimental context, preferably with models that include elements of the human mucosal barrier 63 response. It is only in this context of a multi-factorial study design that the most translationally 64 relevant biological findings can be identified and validated in primary human donor tissues. 65
Results

67
CDAD-associated antibiotics induce distinct changes to host gene expression
68
To test the commensal-independent effects of antibiotics on the host, we used a transwell-based 69 in vitro epithelial barrier without bacteria to model a germ-free human gut 21, 22 . We treated mature 70 mucosal barriers with antibiotics with CDAD odds ratios, from one (no risk) to 17 (highest risk; 71 Supplemental Table 1 ) in order to achieve complete coverage of the CDAD risk landscape. We 72 dosed from the basal side to mimic intravenous administration due to its increased risk of CDAD 23 , 73 using clinically-relevant dose ranges. Tigecycline is an intravenous tetracycline derivative that 74 does not increase the risk of CDAD 24 . We used clindamycin and ciprofloxacin for CDAD-75 associated antibiotics as they have the highest risk of CDAD 24,25 . Tigecycline and clindamycin 76 share a similar mechanism of action, both targeting bacterial translation machinery. Conversely, 77 ciprofloxacin inhibits bacterial DNA replication. All three are considered broad-spectrum 78
antibiotics. 79
After 24 hours of exposure, RNA-seq identified gene expression changes under high and low 80 treatment conditions, with the largest number of transcriptional changes being driven by 81 ciprofloxacin treatment ( Fig 1B-E) . We found DMSO treatment at high concentration had 82 significant effect on gene expression, and therefore performed subsequent analysis using the low 83 concentrations of both DMSO and tigecycline (Supplemental Fig S1) . 84
Unsupervised hierarchical clustering of the 606 genes with statistically significant gene 85 expression changes in at least two treatment groups revealed antibiotic-specific alterations of the 86 gut transcriptome (Supplemental Fig S2) . This clustering showed varying patterns of 87 transcriptional response to treatment: several transcripts shared similar expression configurations 88 across experimental conditions, some had dose-dependent effects correlating to increasing or 89 decreasing CDAD risk, still others exhibited more complex behaviors not apparent from the initial 90 clustering. However, the ciprofloxacin-driven expression changes dominated the clustering, 91 highlighting the need for more nuanced computational analysis. 92
In order to identify genes with transcriptional changes shared between both CDAD-associated 93 antibiotics, we used a self-organizing map (SOM). A SOM is a neural network-based unsupervised 94 clustering technique that groups similar observations together on the SOM neurons. Here, we used 95 the SOM to cluster gene transcript fold changes across antibiotic treatments to identify genes with 96 expression changes associated with CDAD risk. Similar to other dimensionality reduction 97 techniques, such as principal components analysis (PCA), SOMs produce a low-dimensional 98 projection of high-dimensional data that facilitates visualization of patterns. However, unlike PCA 99 or our previous hierarchical clustering, the SOM analysis merges two important features 100 simultaneously: (i) it incorporates information about the expected number of clusters in the data by defining the number of SOM neurons based on experimental design (number of conditions); 102 and (ii) it allows the data to drive identification of the most informative groups among those 103 clusters (i.e., SOM neurons). 104
The architecture of the SOM employed here to map the 606 significant genes is based on 105 increased or decreased gene expression (2 directions) in each of three (3) experimental conditions, 106 with an extra neuron for noisy profiles (2 3 +1=9 neurons). Genes with similar expression patterns 107 cluster in a node, with the number of genes per node indicated ( Fig. 2A ). Plotting neighbor weight 108 distances allows for the visualization of similarities between nodes ( Fig. 2B) . 109
Each neuron of the SOM captured gene expression responses to antibiotic treatment that 110 grouped according to changing CDAD risk ratios. These patterns could then be investigated by 111 plotting line graphs of the gene fold changes across increasing CDAD risk for each node (Fig. 2C ). 112
Two nodes identified gene expression responses that were specifically elevated (Node 3) or 113 repressed (Node 7) in response to CDAD-associated antibiotic treatment. Another two nodes (4 114 and 6) captured risk ratio-dependent changes in gene expression responses to CDAD-associated 115 antibiotic treatment, with genes on Node 4 being more downregulated and genes on Node 6 being 116 more upregulated in antibiotics with higher CDAD risk ratios. Altogether, nodes 3, 4, 6, and 7 117 capture a set of 261 genes with expression patterns common among ciprofloxacin and clindamycin 118 that indicated a shared pattern of expression unique to the CDAD-associated antibiotics (Fig. 2C) , 119 despite different mechanisms of action between ciprofloxacin and clindamycin, and tigecycline 120 and clindamycin being similar. 121
In order to identify the biological functions associated with CDAD-associated antibiotic 122 treatment, we performed Gene Ontology Enrichment Analysis (GOEA) of each node (Fig. 2D , 123
Supplemental Table 2 ). We would expect nodes that cluster by mechanism of action to be enriched 124 in related GO terms. For instance, the gene expression responses common to tigecycline and 125 clindamycin (Nodes 2 and 8) were enriched for the cellular targets of those drugs, translation 126 machinery and chromosome maintenance ( Fig. 2D ). It is important to note that these targets are 127 considered bacterial cellular components, yet we found they impacted mammalian cells. This 128 finding from the SOM clustering that grouped known target-associated gene expression responses 129 to tigecycline and clindamycin provided an important positive control for interpreting the 130 biological functions associated with the other SOM neurons. 131
We then analyzed the SOM clusters that captured genes with shared expression response 132 patterns to CDAD-associated antibiotics (Nodes 3, 4, 6, and 7), and distinct from low risk, to 133 generate mechanistic hypotheses of host-dependent mechanisms of CDAD. The GOEA functional 134 annotations of CDAD-associated antibiotic treatment showed an accumulation of cellular toxins 135 in the cell via retrograde secretion (Node 3: toxin transport) coupled with a decrease in secretion 136 out of the cell (Node 7). We found that as antibiotic CDAD risk ratios increased, genes associated 137 with immune signaling GO terms were suppressed (Node 4) and genes associated with cell-cell 138 and cell-ECM connections were increased (Nodes 6 and 7) in a dose-dependent manner. Overall, 139 GOEA of these SOM suggested that treatment with CDAD-associated antibiotics resulted in 140 alterations to transport of extracellular components out of the cell, toxins into the cell, and a 141 reduced immune capacity after only 24hrs of treatment. 142
CDAD-associated antibiotics reduce mucosal barrier and immune functions
144
Based on the results of the SOM analysis, we hypothesized that CDAD-associated antibiotic 145 treatment would result in acute effects of impaired epithelial barrier and innate immune cell 146 function and that these would be present after chronic exposure as with in vivo antibiotic treatment 147 patterns. We tested these SOM predictions experimentally using three complementary levels of in 148 vitro models: (i) acute effects (24 hr) on epithelial barrier function; (ii) chronic (3 days) effects on 149 epithelial exposure to toxin; and (iii) acute effects on innate immune cell function. We assessed 150 the barrier function of mucosal barriers following antibiotic treatment. We find increased death of 151 cells in the monolayers with ciprofloxacin treatment, which agrees with previous work using 152 significantly higher concentrations 26 , and clindamycin, which has not previously been 153 demonstrated (Supplemental Fig S3) . Despite this, none of the antibiotics used affected the 154 physical integrity of the barrier as determined by transepithelial electrical resistance 24 hours post 155 treatment (Supplemental Fig S4) . 156
To better mimic the 3-7 day course of antibiotics in routine in vivo human treatment patterns, 157
we extended the treatment period to a 3 day basal dose. We quantified both mucin gene expression 158 and secretion as they strongly influence microbial interactions with the mucosal barrier. Total cell-159 bound (Fig. 3A ) mucin was reduced with CDAD-associated antibiotics, while mucins in low risk 160 CDAD treatment groups remain unchanged (Fig. 3A, B ). Secreted mucins were reduced with both 161 CDAD-associate antibiotics, though the clindamycin treatment group does not reach statistical 162 significance ( Fig 3B) . This is recapitulated in primary cell-derived 2D enteroids: one of the main 163 membrane-bound mucins in the colon 27 , muc17, is reduced with ciprofloxacin but not clindamycin 164 or tigecycline treatment ( Fig. 3C ), suggesting another mucin is altered with clindamycin treatment 165 to account for the loss of total cell-bound mucins. 166
To assess the effect of extended, low-dose antibiotic treatment on immune function, we treated 167 an immune-competent mucosal barrier for 3 days with each antibiotic, again dosing from the basal 168 side. IL-8 secretion is the primary chemokine implicated in CDAD 28 . IL-8 is required for 169 neutrophil recruitment to contain the infection, yet neutrophils are also implicated in progression 170 of disease 29 . Thus, a delicate control over dissemination and clearance of neutrophils is likely 171 required for resolution of infection. 172
We therefore assessed the effect of antibiotics on the ability of immune-competent mucosal 173 barriers to induce il8 expression and IL-8 secretion following LPS stimulation. LPS signals 174 through TLR4 and tlr4 gene expression should increase following its activation, yet tlr4 expression 175 did not increase with LPS stimulation following ciprofloxacin treatment ( Fig 3D) . Clindamycin 176 treated barriers had lower levels of tlr4 relative to vehicle, though this was not significantly lower 177 than for tigecycline by student's t test ( Fig 3D) .We found il8 gene expression ( Fig. 3E) is reduced 178 following ciprofloxacin and clindamycin treatment but unchanged with tigecycline in LPS-treated 179 barriers. IL-8 secretion (Fig. 3F ) was reduced to a statistically significance extent in all treatment 180 groups. It is likely the magnitude of change is important in the case of CDAD-associated 181
antibiotics. 182
To test whether the immune cells are impaired in function, we performed phagocytosis and 183 killing assays using GFP+ E. coli. We find that pre-treating macrophages with CDAD-associated 184 antibiotics reduce both phagocytosis of E. coli (Fig. 4A ) and subsequent killing of phagocytosed 185 E. coli (Fig. 4B ). Together, these data confirm loss of immune responsiveness with CDAD-186 associated antibiotics, which one can imagine might contribute to outgrowth of C. difficile. 187 
A B
Discussion 207
Here we demonstrate the convergent changes to the host from two separate CDAD-associated 208 antibiotics in the absence of commensal bacteria. CDAD has been suggested to be a multi-phase 209 system, where germination, outgrowth, and toxin production each have distinct signals upon which 210 they activate 31 . Substantial work has shown that antibiotics contribute to CDAD by changing 211 commensal structure and removing inhibition on both germination and outgrowth 32 . Yet, the 212 specific structural definition of a CDAD-inhibitory gut microbiome remains elusive. 213
Our data suggest a potential mechanism by which an already outgrown but microbiome-214 controlled population of C. difficile might be able to take hold and produce toxin following the 215 host changes of CDAD-associated antibiotics: loss of mucin barrier, increased sensitivity to toxin, 216 and reduced innate immune response. We found that both CDAD-associated antibiotics lead to 217 increased toxin transport (Fig. 2D) and concomitant sensitivity to toxin B (Fig. 4C, D) . 218
Increased relative abundance of proteobacteria is associated with CDAD and has been proposed 219 to be a risk factor 33 . Proteobacterial bloom following antibiotic treatment might be accounted for 220 by the loss of E. coli and LPS responsiveness we uncovered. 221
Host-directed therapies might circumvent recurrent or drug resistant infection or prevent CDAD 222 completely. Host response is a better predictor of patient outcome than specific changes to the 223 microbiome or even than C. difficile bacterial load 34 , suggesting host stratification might be 224 effective in preventing CDAD. Future work is required to identify potential host-directed therapies 225 that might increase mucin production or innate immunity in the colon of patients taking high risk 226
antibiotics. This work suggests using caution when prescribing CDAD-associated antibiotics, 227 particularly to those at higher risk for CDAD. 228
Our work defines a new role for effects of CDAD-associated antibiotics on CDAD pathology, 229 namely, the commensal-independent effects on the host. By reducing barrier function and immune 230 cell capability and increasing toxin sensitivity, antibiotics with high risk for CDAD may prime the 231 host to be less prepared for combating C. difficile infection and pathogenesis. This has important 232 implications for potential host-directed prophylactic or CDAD-treatment therapies. Further work 233 is needed to understand the commensal-independent effects of other antibiotics that might 234 similarly prime the gut for enteric infection. iCiGiCACACTCTTTCCCTACACGACGCrGrGrG-3' where iC: iso-dC, iG: iso-dG, rG: RNA 321 G ]) and incubation at 42C for 90' followed by inactivation at 72C for 10'. Following the 322 template switching reaction, cDNA from 24 wells containing unique well identifiers were pooled 323 together and cleaned using RNA Ampure beads at 1.0X. cDNA was eluted with 90 ul of water 324 followed by digestion with Exonuclease I at 37C for 45 minutes, inactivation at 80C for 20 325 minutes. Single stranded cDNA was then cleaned using RNA Ampure beads at 1.0X and eluted 326 in 50ul of water. Second strand synthesis and PCR amplification was done using the Advantage 327 2 Polymerase Mix (Clontech) and the SINGV6 primer (10 pmol, Integrated DNA Technologies 328 5'-/5Biosg/ACACTCTTTCCCTACACGACGC-3' ). 12 cycles of PCR was performed followed 329 by clean up using regular SPRI beads at 1.0X, and was eluted with 20ul of EB. Successful Gene ontology enrichment on all GO terms was performed using the free online PANTHER 372 overrepresentation test [38] [39] [40] . FDR was set to <0.05. 373
